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Abbreviations 
AATD Alpha 1 antitrypsin deficiency  VGDF Vapours, gases, dust and fumes 
COPD Chronic obstructive pulmonary disease BHR Bronchial hyperresponsiveness 
NE Neutrophil elastase TLCO Transfer factor of the lung for 
carbon monoxide 
FEV1 Forced expiratory volume in one second FVC Forced vital capacity 
KCO Carbon monoxide transfer coefficient 
(TLCO/alveolar volume) 
VC Vital capacity 
CT Computerised tomography   
PM10 Particulates with diameter <10µM   
ABSTRACT  
Environmental influences on clinical phenotype in AATD include cigarette smoke, 
occupational exposures, airway/sputum bacteria and outdoor air pollution. This 
narrative review describes the impact of the major environmental exposures and 
summarises their effect on clinical phenotype and outcomes. In general patients with 
AATD are more susceptible to pulmonary damage as a result of relatively unopposed 
action of neutrophil elastase, in the context of neutrophilic inflammation stimulated by 
environmental factors. However the amount of phenotypic variability explicable by 
environmental factors is insufficient to account for the wide range of clinical 
presentations observed, suggesting that a combination of genetic and environmental 
factors are likely to be responsible. 
 
  
INTRODUCTION 
Alpha 1 antitrypsin deficiency (AATD) is the only widely accepted genetic risk factor for 
chronic obstructive pulmonary disease (COPD) and emphysema, but there is wide 
variability in clinical presentation (1). Many factors are likely contribute to this, and to 
interact with genetic factors in the classical ‘disease susceptibility + environment’ 
manner that is common to many chronic diseases. Environmental factors are a 
particularly attractive area for clinicians to focus on as they are potentially modifiable, 
hence influence our discussions with patients about their current exposures, and how 
they might alter them to minimise risk of disease. In order to discuss which 
environmental factor may be important to AATD patients, we first need to think about 
what our environment actually is, and which manifestations of AATD such exposures 
may modify. The dictionary definition or environment is ‘the external conditions in 
general affecting the life, existence, or properties of an organism or object’(2); in this 
sense any inhaled or ingested agent would be considered part of the environment, since 
it exists external to the patient, so we need to consider which of these affect pathology 
in AATD.  
Conceptually social factors would also be considered part of the environment, though 
these are poorly studied for their relationship to pathology independent of their 
relationship to exposures within that environment. For example, low socio-economic 
status is associated with higher rates of cigarette smoking (3), and health detriments 
may occur from smoking, but could be influenced by other coexisting factors in the 
social environment. This narrative review will therefore focus on those external 
influences which have been studied to a reasonable degree in AATD, and affect the lung, 
namely cigarette smoking, air pollution and occupation. We will then consider whether 
airway microbiota can be considered within the dictionary definition of environmental 
factors relevant to AATD or not. Finally, the environmental influences on disease 
outside the lung will be discussed briefly. 
 
EFFECTS OF CIGARETTE SMOKE 
In AATD one of the main drivers of lung pathology is protease imbalance, mediated by 
the relative deficiency of AAT, and hence unopposed action of neutrophil elastase (NE) 
and other proteases (4). The mechanism by which this occurs is illustrated in figure 1. 
Whenever a neutrophil enters the lung there is an obligate area of damage associated 
with the release of NE, which in AATD is larger than in individuals with normal AAT 
levels since it is unopposed. Smoking stimulates neutrophilic inflammation in the lung, 
and hence the amount of NE mediated damage to the lung in AATD is larger than in 
smokers who have normal AAT levels.  Once COPD is present this also influences 
neutrophil transit in the lung (5), hence there is the possibility of exacerbating 
pathogenic processes dependent on the neutrophil, though it is possible neutrophil 
transit changes are exclusive to usual COPD, as in vitro work suggest PiZZ neutrophils 
have normal chemotactic activity(6). Aging may  modify the effect of smoke exposure on 
neutrophilic inflammation in mice(7), and it is possible this effect exists in man, given 
that smoke exposure in older age appears more deleterious(8). In addition smoke 
exposure may alter the inherent immunological and oxidative properties of AAT in a 
detrimental way (9, 10), and in polymeric forms of AATD may drive polymerisation(10). 
Polymers themselves drive inflammation (11), hence the effects of smoking in AATD 
may be further magnified by secondary accumulation of polymers.  
This wealth of mechanistic data supporting harmful effects of cigarette smoke is 
supported by clinical observations. Patients with AATD who smoke, or have smoked, are 
more likely to exhibit COPD and emphysema, and the relevant physiological markers of 
these conditions, specifically lower FEV1 and gas transfer coefficient (KCO), than those 
with less or no smoke exposure(12, 13). The prevalence of chronic bronchitis appeared 
unrelated to smoke exposure in our data (12); this is perhaps surprising since early 
onset chronic bronchitis outside AATD is associated with smoke exposure(14). The 
AATD genotypes have variable levels of risk dependant on enzyme levels. PiMM 
individuals have normal levels of AAT and thus smoking results in the same risk of 
COPD as normal individuals (15). PiMZ are at a slightly increased risk of emphysema 
(16), but do not develop lung disease in the absence of smoking (17); FEV1/FVC ratio 
and FEV1% predicted were significantly decreased compared to PiMM individuals, with 
a higher rate of FEV1 decline in PiMZ ever-smokers. The following discussion references 
studies primarily relating to people with the PiSZ and PiZZ genotypes who may develop 
lung disease in the absence of smoking.   
Smoking also influences lung function decline, with the most marked harm coming from 
current cigarette use (18-21); effect sizes of current smoking have varied in the studies 
that reported it, but are invariably damaging. The amount smoked in terms of pack 
years is also relevant, in that threshold effects have been reported in both American and 
UK data for patients with PiZZ AATD(18, 22), whereby it seems that after 20 pack years 
there is no longer a relationship between FEV1 and exposure. In patients who are PiSZ 
this threshold rises to 30 pack years(18), consistent with the higher AAT levels that 
such patients generally have, and the known relationship between greater area of 
obligate NE mediated damage and AAT level. Some caution must be exercised when 
considering these putative thresholds as the data from which they were generated does 
show marked scatter, consistent with multiple influences (both genetic and 
environmental) on FEV1 - indeed the amount of variability in FEV1 explicable by pack 
years smoked was just 15% in UK data (12). The duration of smoking may also be 
relevant, as data from the German registry demonstrates that longer durations associate 
with faster subsequent FEV1 decline(23); teasing out the differences between 
cumulative exposure (pack years) from duration is clearly difficult and requires further 
research. Age at onset of smoke exposure may also be critical, as demonstrated by 
Mayer et al in a survey of patients with PiZZ AATD, which reported earlier onset of 
symptoms in those exposed to smoke passively in childhood(24). Passive smoke was 
also a risk factor for lung disease in an independent study, albeit of only 52 PiZZ 
patients(25). Whether age at onset is a risk independent of total amount or duration is 
unknown. Interestingly data, such as that from the Swedish registry(26), has reported 
that after smoking cessation FEV1 decline may return to that of a never smoker. This 
emphasises the importance of smoking cessation at any time of life in patients with 
AATD, and perhaps suggests that the relationship between pack years smoked and 
FEV1 is largely related to damage incurred during the period of active smoking.  
Smoking may also relate to a higher exacerbation frequency, and concomitant 
deterioration in quality of life over time, as shown in the German registry (27, 28). 
Whilst relatively few studies have reported influences on exacerbations in AATD, the 
strong influence of smoking on exacerbation rate in COPD outwith AATD implies that 
this may be a true finding, irrespective of published replication in other cohorts.  
Further research about smoking in AATD might focus on improving our understanding 
of specific phenotypic associations as that has been limited by lack of detailed 
phenotyping in many AATD cohorts internationally, in particular there have been 
relatively few quantitative CT studies in AATD outside the context of clinical trials, 
when compared to usual COPD, and few studies that have data on small airways disease 
whether measured physiologically or radiologically. The COPDgene study emphasises 
the value of CT studies in progression of emphysema and air trapping(29). Radiographic 
progression was found to have variable correlation to FEV1 (29), and better association 
to rate of DLCO decline especially in severe disease (30). There is no data available on 
other inhaled smoke types, such as cannabis, heroin or other drugs of abuse, or of 
vaping with lung disease in AATD, but since these are known to be harmful in people 
with normal AAT levels (31), we can reasonably presume that they will be more 
harmful in AATD. 
 
EFFECTS OF OUTDOOR AIR POLLUTION 
There are a number of pollutants potentially relevant to lung disease risk, of which the 
most important in the general COPD literature are particulate matter and ozone. Studies 
of outdoor air pollution in AATD have conducted by our group in the UK in PIZZ 
patients, and reported for PiMZ patients by a European group. In PiZZ AATD patients we 
found that a surrogate measure for lifelong exposure to ozone, namely current ozone 
level as determined by geocoding of pollution (geographical information system 
mapping, down to a 1km level, based on the patients’ home address)  related to lower 
FEV1 and KCO at enrolment to the cohort(32), after adjustment for cigarette smoke 
exposure and other relevant demographic features. The effect of ozone was relatively 
small, with the difference in ozone seen between urban and rural environments 
associating with a difference of 2% in KCO, and overall ozone exposure accounting for 
1% of KCO variability. AAT levels in the lung are elevated after exposure to ozone (33), 
and AAT offers over 80% of pulmonary defence against ozone induced inflammation 
(34). This suggests a rationale for enhanced susceptibility to ozone in AATD. However 
the use of cross-sectional data had limitations, as was demonstrated by the data for 
PM10 (particulates with diameter <10µM) where current high levels appeared to relate 
to better lung function. At a biological level this seemed implausible, given that 
particulates stimulate neutrophilic inflammation to which patients with AATD would be 
more vulnerable in terms of lung damage. We therefore went on to study true 
cumulative exposure with respect to lung function decline; whilst the range of values 
seen for lung function decline was not as wide as the range seen in baseline data for 
each lung function parameter (thus potentially limiting power to detect pollution 
effects) the model was almost certainly more robust when considering accuracy of 
pollution data. This study showed that PM10 adversely affected FEV1 decline, and 
ozone related to decline in KCO(35). Once more effect sizes were small, with an increase 
of 1µg/m3 in PM10 exposure relating to an additional 3ml/year of loss in FEV1.  
One study in the SAPALDIA cohort demonstrated in short term follow (2001-2003) that 
PM10 exposure did not appear to interact with AATD genotype with respect to FEV1 
decline, however the only statistics generated were on PiMZ individuals in the study 
(comparing to PiMM as the reference)(36). This suggests that the effect of pollution on 
decline is lost in lower risk genotypes, or is so subtle as not to be detectable in a short 
period of follow up. This is consistent with the UK data from PiZZ patients and the 
concept that lower AAT levels carry corresponding increased risks from environmental 
insults. Confirming this, a study of a single large exposure to environmental dusts, after 
the collapse of the world trade centre (9/11) demonstrated increased FEV1 decline in 
exposed PiMZ and PiSZ firefighters relative to normal genotypes(37).  
 
THE INFLUENCE OF OCCUPATIONAL EXPOSURES 
There are a number of occupational exposures which could stimulate pulmonary 
inflammation, and hence be of greater risk to patients with PiZZ AATD compared to 
normal individuals. Occupational exposure is often assessed in large epidemiological 
studies by use of self-reported exposure to vapours, gases, dusts and fumes (VGDF), 
which are relevant to development of airways disease. This is an accepted method of 
reporting such data, but potentially less accurate in comparison to a full occupational 
history, whereby the job the patient did is used to assign the level of risk. This is usually 
done via a job exposure matrix (38) which classifies jobs for their likely level of risk 
using Standard Occupational Classifications (eg SOC 2000) generated using a recognised 
system (eg CASCOT (39)). Whilst this is more accurate it is also much more time 
consuming, and relies on patients remembering all the jobs they have done. 
An early study in 52 PiZZ patients identified that lower FEV1 was observed in those 
reporting VGDF exposure, albeit not statistically significant (p=0.07)(25). More recently 
exposure to VGDF (or an equivalent self-reported measure) has been assessed in AATD 
by Germany, Sweden, National Jewish Health and SAPALDIA, comprising 451 PiZZ, 6 
PiSZ and 220 PiMZ subjects altogether (23, 36, 40-42). Results of these studies are 
summarised in table 1. In general VGDF exposure associated with increased 
symptomatology, reduced lung function and lung function decline (23). In PiMZ carriers 
an interaction was seen between genotype, smoking and VGDF exposure such that those 
carrying a Z allele, smoking and having VGDF exposure were more likely to exhibit 
deterioration in their small airways (as measured by FEF25-75)(36). In PiZZ patients 
agricultural employment in particular associated with lower FEV1 and increased 
bronchial hyperresponsiveness (BHR) (41, 42); increased BHR was also seen in PiMZ 
subjects but the risk was approximately half that of a PiZZ person. In addition to 
farmers, those in the timber industry (e.g. wood trimmers, furniture making, sawmills) 
are at higher risk of allergic alveolitis and lung cancer (43). Whilst this study (43) was 
not specific to AATD it is probable the same, or enhanced, risks apply since studies have 
linked wood dust exposure to increased antibody secretion resulting in airway 
inflammation (44), which then may result in decreased FEV1 and increased FEV1 
decline (45) in normal individuals. In any pro-inflammatory insult like this people with 
AATD are likely to be more at risk due to reduced inhibition of inflammation. 
In our own data (previously published only in abstract form(46)) we took a different 
approach, and classified occupational risk using a job exposure matrix, from the full 
occupational history. Data was available on 379 PiZZ patients, and risk was allocated 
according to likelihood of exposure to a risk agent, determined by an occupational hygienist. If 
the intensity was likely to be less than 30% of the workplace exposure limit this was 
classed as low risk, with intensities above this being deemed high risk. Those who had 
never worked in an exposure prone job were classed as zero risk. Patients had worked 
for a mean of 19 years, and stopped work on average at age 48 years if cessation was 
due to lung disease. There were no differences in duration of working life or age when 
stopped work between risk groups. Characteristics of the patients are shown in table 2; 
no elements of lung function differed between risk groups. Whilst our results contradict 
others data there are several possible explanations for this; firstly it is possible our 
methods were more robust and specific to occupational exposure than other self-
reported studies, in which VGDF exposure might have been overestimated due to recall 
biases. Secondly, it is possible that the use of a general job exposure matrix rather than 
one specifically selecting airways disease could have influenced results; this would have 
been difficult to do, since many professions exposed to agents known to lead to 
interstitial or fibrotic disease (eg asbestos in building trade) also have exposure to 
agents known to influence airways disease (eg wood dusts in building trade). Thirdly it 
might be that confounding was influencing results; in order to assess the latter issue we 
looked specifically at lung function decline according to occupational risk, adjusting for 
both pollution, smoke exposure and other relevant covariates, and found enhanced KCO 
decline in high risk occupations relative to those with zero risk, with enhanced FEV1 
decline also being seen in female workers in high risk jobs (47).  
There have been few studies of non VGDF exposures in AATD. However one study of 
asbestos exposure reported an increased risk of asbestosis in carriers of the S or Z allele 
(48). The number of patients was small, and the mechanism less clear than it would be 
for airways disease, so further studies of fibrotic lung diseases in AATD patients would 
be required to say if there is enhanced risk of pulmonary pathology outside of the 
airway. Notably in our dataset reported above no subjects exhibited restrictive lung 
function or interstitial lung disease on HRCT, even though risk professions potentially 
linked to asbestos (eg construction work) were amongst the most common risk groups 
seen. 
 
ARE AIRWAY BACTERIA A RELEVANT ENVIRONMENTAL FACTOR? 
The presence of bacteria in the sputum or airway could be considered a relevant factor, 
since they are acquired from the environment around us and influence clinical 
phenotype. Bacterial colonisation of the airway may influence exacerbation rate, health 
status(49) and subsequent lung function decline in usual COPD, and since bacterial 
events involve neutrophilic inflammation(49, 50) conceivably these effects would be 
enhanced in patients who have AATD. There is some evidence that this is the case, with 
exacerbating AATD patients exhibiting more inflammation than those with usual COPD 
(51), and those with colonisation exhibiting greater immune activation, as measured by 
free light chain level in the blood (52). However colonisation itself may be influenced by 
genetic modifiers in AATD (53), implying that gene-environment interaction exists and 
thus it may be difficult to separate phenotypic features due to exposure to infection, 
from those due to underlying genetic influences.  
There is growing evidence that the bacteria we culture are not the only relevant part of 
the microbial environment, with studies in other airway diseases demonstrating 
changes in inflammation(54) and clinical phenotype dependent on type of micro-
organisms, as measured by 16s DNA analysis(55, 56), and on outcome, specifically 
mortality(57). Ongoing analyses of the microbiome in AATD as part of the GRADS 
research programme (NCT01832220) will therefore be of interest in future, to aid 
understanding of this environmental factor. 
 
ENVIRONMENTAL INFLUENCES INFLUENCING DISEASE OUTSIDE THE LUNG 
Since ingested substances may be considered part of the environment, it is worth noting 
that alcohol is a recognised co-factor in development of liver fibrosis and cirrhosis when 
the Z allele is present(58). However, unlike smoke exposure in the lung where there is a 
synergistic interaction between genotype and environmental exposure the mechanism 
of AATD liver disease is not enhanced by alcohol, and the association is likely observed 
simply due to additive effects of environment and genotype. Nevertheless AATD 
patients should be advised about the risks of alcohol to the liver, in order to minimise 
risk of long term complications. 
 
CONCLUSIONS 
Patients with AATD have enhanced susceptibility to inflammatory stimuli in the 
environment, predominantly cigarette smoke, although air pollution and occupational 
inhalational exposures also play a part. The degree of variability in respiratory 
presentation accounted for by environmental factors is difficult to accurately quantify 
but undeniably is linked to lung disease progression in AATD patients.  
  
Reference N & 
genotype  
Exposure type Clinical findings 
Fahndrich 
et al. (20) 
PiZZ  
N=100 
FEV1  
N=116 
TLCO 
• Smoking  
• Exacerbations  
• Occupational 
dusts 
• ↑ FEV1decline associated with 
occupational dust exposure, shorter 
duration of smoking abstinence, and an 
increased frequency of exacerbations 
per year.  
 
Mehta et 
al. (31) 
PiMZ  
N=97  
• Pollution 
(PM10) 
• Occupational  
VGDF 
• No significant clinic findings for PM10 
• ↑FEF25-75 & FEV1/FVC decline in 
VGDF exposed smokers v PiMM  
 
Mayer et 
al. (35) 
Pi*ZZ 
N=128  
• Smoking  
• Occupational 
dust, fumes, 
smoke and gas 
• ↑mineral dust associated with cough, 
leaving employment due to 
breathlessness, ↓ FEV1 and ↓FEV1/FVC  
• Exposure to occupational fumes or 
smoke associated with ↓FEV1/FVC 
ratio. 
 
Piitulainen 
et al (36)  
PiZZ  
N=205 
 
• Agricultural 
work 
• Passive 
smoking  
• Indoor 
pollution 
• Agricultural work  >10 years associated 
with wheezing and chronic bronchitis 
• Exposure to kerosene heaters (not gas 
cookers) and agricultural work 
associated with ↓FEV1% & VC  
• Passive smoke >10 years associated 
with chronic bronchitis 
Sigsgaard 
et al. (37) 
PiZZ N=2 
PiSZ N=6 
PiSS N=4 
PiMZ 
N=123 
 
• Farming work  • Increased odds ratio for BHR with PiSZ, 
SS, ZZ alleles (4.34) in farming school 
attendant group compared to control 
group. 
Table 1: Summary of studies of occupational risk according to AATD genotype  
 
Level of occupational risk p 
value 
Zero Low High 
Gender (%♂) 60.9 67.7 50.7 ns 
Age 50.40 (0.8) 48.8 (1.3) 49.2 (1.3) ns 
Pack years 14 (0.2-26) 13.5 (5.3-24.5) 15.8 (0-24) ns 
FEV1 (% 
predicted) 
36.7 (25.8-58.9) 39.9 (24.1-
68.5) 
34.7 (25.9-69.9) ns 
FEV1/FVC (%) 38.2 (29-53) 41(30.6-57) 39.1 (32-60.3) ns 
KCO (gas transfer 
coefficient) % 
predicted 
68.9 (57.4-88.8) 69.9 (2.8) 66.1 (57-85.9) ns 
Bronchodilator 
reversibility (% 
of patients with 
reversibility 
present) 
62.2 64.7 59.5 ns 
Table 2: Characteristics of PiZZ patients studied using a job exposure matrix 
Bronchodilator reversibility was defined as >12% improvement in FEV1 after 
administration of a nebulised bronchodilator, with an improvement which was also at 
least 200ml in volume 
 
 
Figure 1: Mechanism of damage from neutrophilic inflammation in the AATD lung 
The figure shows migration of neutrophils from the blood into the airspaces of the lung, 
with normal lung shown on the left and AATD on the right. Inflammation triggers 
normal immunological responses resulting in increased AAT release due to neutrophil 
recruitment and release of neutrophil elastase (NE). Smoking also releases reactive 
oxygen species (ROS), causing increased neutrophil recruitment and subsequent 
increase in NE and AAT. Different mutations in the SERPINA1 gene result in varying 
amounts of AAT deficiency. Unopposed NE action causes alveolar destruction by 
proteolysis resulting in emphysema. This is illustrated by the cell on the right of the 
figure, where diffusion of active NE outwards from the cell is greater in AATD than a 
PiMM individual. In addition to this protease imbalance mechanism, polymerisation of 
AAT occurs in the presence of malformed AAT proteins and ROS. Polymerised AAT 
results in increased neutrophil recruitment and further alveolar inflammation. This may 
contribute rapid progression of emphysematous changes in AATD patients.    
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